Newsletter | June 4, 2025

06.04.25 -- Improving LNP Formulation For RNA Therapeutic Applications

SPONSOR

Webinar: Scaling up your E. coli pDNA process from parameter screening to pilot scale with advanced single-use bioreactors

Part 1 in an exciting 3-part webinar series to accelerate your pDNA and mRNA process development. Click here to learn more.

FEATURED EDITORIAL

Leading A tRNA Startup With Alltrna's Michelle Werner

On this week's Business of Biotech, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Werner explains why a single engineered tRNA therapy has the potential to treat "hundreds, if not thousands," of rare genetic diseases, and how her own child's rare disease diagnosis shaped her career and approach to drug development. Werner also discusses Alltrna's use of AI and machine learning for drug optimization, the company's planned use of basket trials, and more.

How Can We Improve LNP Formulation For Therapeutic Applications?

Life Edit Therapeutics’ April Sena and Tune Therapeutics’ Tyler Goodwin delve into where they see limitations in downstream processing technologies impacting our ability to scale-up high-quality mRNA-LNPs for large scale therapeutics.

A Road Map For PAT Monitoring And Control

Process analytic technology monitoring and control is rapidly progressing. BioPhorum shares new best practices on how to move from concept through life cycle management and/or regulatory approval of the PAT application.

INDUSTRY INSIGHTS

Optimizing siRNA Therapeutics: Addressing Manufacturing Complexities

Discover key strategies to optimize siRNA therapeutics by addressing critical nonclinical and manufacturing challenges for a smoother path to commercialization.

Probing RNA Base Pairing And Ligand Interactions With Infrared-Based MMS

Discover why Microfluidic Modulation Spectroscopy (MMS) is a novel, label-free, solution-based infrared technique for probing RNA base pairing and ligand interactions.

Enabling GMP Production Of sgRNA For CRISPR-Based CGTs

Explore critical steps and key regulatory requirements for developing CRISPR therapeutics and gain practical advice on how to avoid common pitfalls.

Nanoscale Technology's Potential: A Fireside Chat With Industry Leaders

Nanoform CEO Edward Haeggstrom and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca, discuss the potential of nanoscale medicines and delivery devices.

Lessons In Scaling Lipids Production And Purification

The speed at which the pharmaceutical industry is now developing and manufacturing mRNA drug products at large scale is astounding, yet it has highlighted supply chain vulnerabilities to make the required pharmaceutical ingredients such as lipids.

Optimizing mRNA: A Guide To Enhanced Stability, Delivery, And Efficacy

RNA offers exciting potential for vaccines, gene therapies, and personalized medicine, but challenges related to stability, delivery, and manufacturing persist.

Imagine The Future: Enhanced Oligonucleotide Synthesis

Learn about flexible control software that has revolutionized the way method creation, evaluation, and process optimizations for scale-up are completed.

Increasing Productivity Of pDNA Using Sample Displacement Purification

Here, two distinct polishing processes using monoliths are compared: bind-elute (BE) and the more recently developed sample displacement purification (SDP).